Pan Zheng
Principal investigator, leads Oncoimmune Inc.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$7.2MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 21, 2020 | NIH | SBIR Phase II SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | $1.0M | Oncoimmune Inc |
| May 19, 2020 | NIH | SBIR Phase II Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE) | $397K | Oncoimmune Inc |
| Apr 3, 2020 | NIH | SBIR Phase II First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | $400K | Oncoimmune Inc |
| Mar 31, 2020 | NIH | SBIR Phase II A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse | $985K | Oncoimmune Inc |
| Sep 17, 2019 | NIH | SBIR Phase II SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | $3.0M | Oncoimmune Inc |
| Sep 17, 2019 | NIH | SBIR Phase II A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse | $1.0M | Oncoimmune Inc |
| Sep 1, 2019 | NIH | SBIR Phase I A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | $213K | Oncoimmune Inc |
| Aug 29, 2019 | NIH | SBIR Phase II A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | $213K | Oncoimmune Inc |
Peer ranks
Federal funding#134
Awards as PI#190
Patents#273
Companies
- Oncoimmune IncLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.